Startup profile for Accolade: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Accolade funding, valuation and investors

Personalized healthcare navigation and benefits platform for self-insured employers.

Keep track of Accolade

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Not publicly disclosed

Latest known valuation

~$1.2B

IPO · July 2020

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

public

public · Seattle, Washington

Sources: latest valuation event Last verified: 2026-07-25

Overview

Accolade provides personalized healthcare navigation for employees of self-insured employers — combining human Health Assistants with software to help members choose providers, understand benefits, and resolve medical bills. Founded in 2007 in Seattle, Accolade went public on Nasdaq (ACCD) in July 2020, raising $253.6M at roughly $1.2B valuation; Andreessen Horowitz held approximately 16.2% pre-IPO per GeekWire. The company later went through public-market evolution including go-private transactions — verify current status via SEC filings.

Why Accolade is interesting

Human Health Assistants plus cloud software help employees use employer benefits — a16z held ~16% pre-2020 Nasdaq IPO (ACCD) before later acquisition take-private dynamics.

Product & use cases

Accolade pairs dedicated Health Assistants with a technology platform integrating employer health plans, claims data, and provider search — aiming to reduce wasted spend and improve member satisfaction vs. calling insurer call centers alone.

  • Employees selecting in-network specialists with Health Assistant guidance
  • Employers reducing healthcare cost trend via better benefits utilization
  • Members resolving billing errors and understanding EOBs with human support

Key facts

  • IPO (Jul 2020): $253.6M on Nasdaq (ACCD); ~$1.2B valuation — GeekWire
  • a16z held ~16.2% pre-IPO per GeekWire
  • Human Health Assistants + benefits navigation platform

Funding history (newest first)

IPO

2020-07 $253.6M gross Valuation: ~$1.2B
  • Public markets

Source: https://www.geekwire.com/2020/accolade-ipo-pricing/

Investors in our directory

Funds linked from Accolade's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz

Competitive landscape

Edge: Hybrid human+tech model predates pure navigation apps — Accolade scaled employer contracts with measurable engagement metrics for Fortune 500 HR buyers.

Employer healthcare navigation is competitive with PE-backed consolidators. Accolade's IPO validated category but public markets punished growth vs. profitability at times. a16z's large pre-IPO stake marks it as a successful exit-era holding; current corporate structure requires SEC verification.

  • Quantum Health direct

    Healthcare navigation for employers; similar advocacy model.

  • Transcarent direct

    Employer health navigation and care delivery; overlapping buyer.

  • HealthJoy adjacent

    Digital benefits navigation; less human assistant emphasis.

Notable stories

  • Accolade's 2020 IPO was a marquee a16z healthcare exit during the COVID-era telehealth and benefits navigation boom (GeekWire).

Industries

Healthtech Enterprise SaaS

Market / IPO context

Ticker: ACCD (NASDAQ)

IPO status: public

IPO date: 2020-07

Editorial / static context — not a live quote.

Related funding articles

Venture Capital Tracker pieces that cover Accolade's financing or category context.

FAQs about Accolade

Practical answers founders, operators, and investors typically search for.

Accolade provides healthcare navigation for employer-sponsored benefits — human Health Assistants plus software helping employees use plans and find care.
Andreessen Horowitz (/fund/andreessen-horowitz) was a major pre-IPO shareholder (~16.2% before July 2020 IPO per GeekWire).
Accolade IPO'd on Nasdaq as ACCD in July 2020. Verify current listing status — company may have gone private in later transactions.
Roughly $1.2B at pricing; $253.6M gross proceeds raised per GeekWire.
Both sell employer healthcare navigation. Accolade emphasizes Health Assistants; compare current product scope on each site.
July 2020 on Nasdaq (ticker ACCD).
Self-insured employers offering Accolade as employee benefit navigation.
Seattle, Washington area.
No — navigation and advocacy layer on top of employer health plans, not an insurer.
a16z was a significant early institutional investor through successful IPO exit era.
Website All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.